Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $15.60.

YMAB has been the topic of several recent research reports. Truist Financial decreased their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. HC Wainwright decreased their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Wedbush reaffirmed an "outperform" rating and set a $18.00 price objective (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. Oppenheimer decreased their price objective on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. Finally, Morgan Stanley decreased their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th.

Y-mAbs Therapeutics Price Performance

YMAB stock opened at $5.27 on Monday. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11. The company has a market capitalization of $238.65 million, a price-to-earnings ratio of -9.76 and a beta of 0.52. The business has a 50 day simple moving average of $4.40 and a two-hundred day simple moving average of $6.10.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. Sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of YMAB. SG Americas Securities LLC raised its holdings in Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock valued at $139,000 after buying an additional 4,163 shares during the period. Principal Financial Group Inc. grew its position in Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock valued at $174,000 after acquiring an additional 1,903 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Y-mAbs Therapeutics by 1.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock valued at $2,228,000 after acquiring an additional 4,963 shares during the last quarter. AlphaQuest LLC grew its position in Y-mAbs Therapeutics by 6,911.6% in the 4th quarter. AlphaQuest LLC now owns 27,135 shares of the company's stock valued at $212,000 after acquiring an additional 26,748 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics in the 4th quarter valued at $46,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.